Ornithine decarboxylase activity in prostate cancer

Authors

  • O.А. Samoylenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • E.O. Stakhovsky National Cancer Institute, Kyiv
  • Y.V. Vitruk National Cancer Institute, Kyiv
  • V.O. Shlyakhovenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.16011

Keywords:

biomarkers, Gleason score, ornithine decarboxylase activity, prostate cancer, prostate-specific antigen

Abstract

Summary. Prostate cancer (PCa), the most common solid malignant neoplasm in men, is characterized using the Gleason score and diagnosed using prostate-specific antigen (PSA) biomarker. However, Gleason score and PSA-based diagnostics are not universal and have significant limitations. It is supposed that the ornithine decarboxylase activity (AODC) could be a suitable auxiliary biomarker for the PCa diagnosis or monitoring the therapeutic efficacy. Aim: To assess the relation between AODC in PCa tissues and the level of serum PSA with the Gleason score (GS) and the clinical stage. Materials and Methods: 29 patients (48 to 79 years old) with prostate adenocarcinoma of different GS (6 to 10) and clinical stage (T1 to T4) were enrolled in the study. The AODC was analyzed in the PCa tissues by the modified spectrophotometric assay. Results: The patients with PCa were distributed into two groups: with low AODC < 0.3 and high AODC > 0.45. In group with AODC < 0.3, the highest value of AODC was recorded in patients with the lowest GS (= 6), while in group with AODC > 0.45, the highest value of AODC was recorded in the patients with the highest GS (= 9–10). Furthermore, in group with AODC > 0.45, the highest value of AODC was registered in the patients with T1 or T4 stage. The highest levels of serum PSA were detected in T3–T4 cases and in cases with the highest GS. Conclusion: The patterns of AODC and serum PSA can be used as supplementary indices useful for monitoring PCa course.

References

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.

CANCER TODAY. Data visualization tools for exploring the global cancer burden in 2020. https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf.

Athanazio D, Gotto G, Shea-Budgell M, et al. Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology 2017; 70: 1098–106.

Dell’Oglio P, Suardi N, Boorjian SA, et al. Predicting survival of men with recurrent prostate cancer after radical prostatectomy. Eur J Cancer 2016; 54: 27–34.

TNM classification of malignant tumours. Eds. Brierley JD, Gospodarowicz MK, Wittekind C. Wiley-Blackwell, 2017, 272 p.

Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273–9.

Miles B, Ittmann M, Wheeler T, et al. Moving beyond Gleason scoring. Arch Pathol Lab Med 2019; 143: 565–70.

Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res 1998; 58: 5425–31.

Schmid-Alliana A, Schmid-Antomarchi H, Al-Sahlanee R, et al. Understanding the progression of bone metastases to identify novel therapeutic targets. Int J Mol Sci 2018; 19: 148.

Carter HB, Pearson JD. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. Urology 1999; 54: 780–6.

Bussemakers MJG, Van Bokhoven A, Verhaegh GW, et al. Dd3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975–9.

Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2: ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 2016; 70: 45–53.

Filella X, Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013; 51: 729–39.

Ito K, Miyakubo M, Sekine Y, et al. Diagnostic significance of [-2] pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range. World J Urol 2013; 31: 305–11.

Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618–29.

Leyten GHJM, Hessels D, Smit FP, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 2015; 21: 3061–70.

Henrique R, Jerónimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004; 46: 660–9.

Van Neste L, Herman JG, Otto G et al. The epigenetic promise for prostate cancer diagnosis. Prostate 2012; 72: 1248–61.

Woodson K, O’Reilly KJ, Hanson JC, et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 2008; 179: 508–12.

NCCN Clinical Practice Guidelines in Oncology, https://www.nccn.org/professionals/physician_gls/default.aspx.

Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18: 3352–9.

Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res 2008; 20: S19.

Barry MJ. Prostate-specific–antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344: 1373–7.

Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988; 48: 759–74.

Tabib A, Bachrach U. Role of polyamines in mediating malignant transformation and oncogene expression. Int J Biochem Cell Biol 1999; 31: 1289–95.

Shukla-Dave A, Castillo-Martin M, Chen M, et al. Ornithine decarboxylase is sufficient for prostate tumorigenesis via androgen receptor signaling. Am J Pathol 2016; 186: 3131–45.

Mohan RR, Challa A, Gupta S, et al. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 1999; 5: 143–7.

Bettuzzi S, Davalli P, Astancolle S, et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000; 60: 28–34.

Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002; 62: 4427–33.

Kaminski L, Torrino S, Dufies M, et al. PGC-1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness. Cancer Res 2019; 79: 3268–80.

Beaven MA, Wilcox G, Terpstra GK. A microprocedure for the measurement of 14CO2 release from [14C] carboxyl-labeled amino acids. Anal Biochem 1978; 84: 638–41.

Luqman S, Masood N, Srivastava S, et al. A modified spectrophotometric and methodical approach to find novel inhibitors of ornithine decarboxylase enzyme: a path through the maze. Protoc Exch 2013; 10.

Adaptation Biology and Medicine: New Challenges. Eds. LM Popescu. AR Hargens, PK Singal. Narosa Publishing House, 2013. 522 p.

Statistical Distributions, 4th edition. Eds. C Forbes, M Evans, N Hastings B Peacock. John Wiley & Sons, 2010. 230 p.

Gilmour SK, Birchler M, Smith MK, et al. Effect of elevated levels of ornithine decarboxylase on cell cycle progression in skin. Cell Growth Differ Am Assoc Cancer Res 1999; 10: 739–48.

Young L, Salomon R, Au W, et al. Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice. J Histochem Cytochem 2006; 54: 223–9.

Shantz LM, Pegg AE. Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. Int J Biochem Cell Biol 1999; 31: 107–22.

Heller JS, Fong WF, Canellakis ES. Induction of a protein inhibitor to ornithine decarboxylase by the end products of its reaction. Proc Natl Acad Sci 1976; 73: 1858–62.

Hoshino Y, Terashima S, Teranishi Y, et al. Ornithine decarboxylase activity as a prognostic marker for colorectal cancer. Fukushima J Med Sci 2007; 53: 1–9.

Downloads

Published

26.05.2023

How to Cite

Samoylenko, O., Stakhovsky, E., Vitruk, Y., & Shlyakhovenko, V. (2023). Ornithine decarboxylase activity in prostate cancer. Experimental Oncology, 43(1), 46–51. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.16011

Issue

Vol. 43 No. 1 (2021): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.